Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in Adult Patients With de Novo Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose Basiliximab 40 or 80 mg in Combination With Cyclosporine Microemulsion, or a Cumulative Dose of 80 mg Basiliximab Without Calcineurin Inhibitor, With Additional Follow-up of 12 Weeks.

Trial Profile

Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in Adult Patients With de Novo Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose Basiliximab 40 or 80 mg in Combination With Cyclosporine Microemulsion, or a Cumulative Dose of 80 mg Basiliximab Without Calcineurin Inhibitor, With Additional Follow-up of 12 Weeks.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Basiliximab (Primary) ; Ciclosporin; Everolimus; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics; Proof of concept; Therapeutic Use
  • Acronyms IDEALE
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top